Brand Intelligence Graphcompany
Company Overview
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.
Business Model & Competitive Advantage
Vertex's CF franchise is built on a succession of increasingly effective CFTR modulator drugs: Kalydeco (2012), Orkambi (2015), Symdeko/Symkevi (2018), and Trikafta/Kaftrio (2019) — the latter treating up to 90% of CF patients and generating over $9B in annual revenue alone. Trikafta has been transformational for the 40,000+ CF patients in the US and 90,000+ globally, dramatically improving lung function and quality of life. Beyond CF, Vertex is expanding into new therapeutic areas with significant pipeline assets: exa-cel (a gene-editing therapy with CRISPR Therapeutics for sickle cell disease, now approved as Casgevy), non-opioid pain treatment (suzetrigine/VX-548, approved January 2025 as Journavx), and kidney disease (VX-147 for APOL1-mediated kidney disease).
Competitive Landscape 2025–2026
Vertex trades on NASDAQ (VRTX) with a market cap of approximately $110B and has one of the strongest balance sheets in biotech (~$12B in cash). CEO Reshma Kewalramani has expanded the company's ambition from a single-disease franchise to a multi-disease platform company, with the non-opioid pain drug Journavx representing a potential blockbuster in a market worth $15B+.
Recent Activity
View all →Key Differentiators
Market Leader
Vertex Pharmaceuticals is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $10.7B in revenue, Vertex Pharmaceuticals operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Compare Vertex Pharmaceuticals with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Vertex Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Vertex Pharmaceuticals Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Vertex Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →